share_log

Evaluating Harmony Biosciences: Insights From 8 Financial Analysts

Benzinga ·  Mar 28 12:00

Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings42011
Last 30D01000
1M Ago10000
2M Ago31000
3M Ago00011

Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.62, a high estimate of $53.00, and a low estimate of $28.00. This current average reflects an increase of 11.42% from the previous average price target of $38.25.

price target chart

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment